2023-2028年世界および地域のデュシェンヌ型筋ジストロフィー（DMD）治療薬産業の現状と展望専門市場調査報告書標準版

2023-2028 Global and Regional Drugs for Duchenne Muscular Dystrophy (DMD) Industry Status and Prospects Professional Market Research Report Standard Version

HNY Research社の最新レポートによると、デュシェンヌ型筋ジストロフィー（DMD）治療薬の世界市場は、2023年から2028年にかけて年平均成長率XX%で推移し、2028年までにXX百万米ドルに達すると予測されている。 ... もっと見る

industry

出版社	出版年月	電子版価格	ページ数	言語
HNY Research HNYリサーチ	2023年9月25日	US$3,500 シングルユーザライセンスライセンス・価格情報注文方法はこちら	142	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

HNY Research社の最新レポートによると、デュシェンヌ型筋ジストロフィー（DMD）治療薬の世界市場は、2023年から2028年にかけて年平均成長率XX%で推移し、2028年までにXX百万米ドルに達すると予測されている。
本レポートの主な目的は、この分野の市場プレイヤーのビジネスアプローチの評価に役立つCOVID-19後の影響に関する洞察を提供することです。また、主要市場、タイプ、用途/エンドユーザー、地域（北米、東アジア、ヨーロッパ、南アジア、東南アジア、中東、アフリカ、オセアニア、南米）による市場細分化もカバーしています。

市場ベンダー別
サレプタ・セラピューティクス
ブリストル・マイヤーズスクイブ
PTCセラピューティクス
WaVe ライフサイエンス
ファイザー
サンテラ・ファーマシューティカルズ
イタルファーマコ

タイプ別
エテプリルセン
デフラザコート
アタルレン

用途別
病院
診療所
在宅医療

主な分析指標
市場プレイヤーと競合分析：本レポートは、会社概要、製品仕様、生産能力/売上高、売上高、価格、売上総利益2017-2028 & 売上高を含む業界の主要プレイヤーを網羅し、市場の競争環境とベンダーの詳細情報、主要市場ベンダーの成長を妨げる要因の包括的な詳細を徹底分析します。
世界市場と地域市場の分析本レポートには、世界＆地域市場の現状と展望2017-2028が含まれています。さらに、本レポートでカバーしている各地域＆国についての詳細な内訳を提供しています。その売上高、販売量、収益予測を特定します。種類別、用途別の詳細分析も掲載しています。
市場動向：競争の激化と継続的な技術革新を含む市場の主要動向。
機会と促進要因：高まる需要と新技術の特定。
ポーターズファイブフォース分析：新規参入の脅威、サプライヤーの交渉力、バイヤーの交渉力、代替製品やサービスの脅威、既存業界のライバルの脅威。

購入の主な理由
市場の洞察に満ちた分析を獲得し、世界市場とその商業状況を包括的に理解する。
生産プロセス、主要課題、開発リスクを軽減するための解決策を評価する。
市場で最も影響力のある推進力と抑制力、および世界市場への影響を理解する。
各主要組織が採用している市場戦略について知る。
市場の将来展望と見通しを理解する。
標準的な構成のレポート以外にも、特定の要件に応じたカスタムリサーチも提供しています。

ページTOPに戻る

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Analysis from 2023 to 2028
1.5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Drugs for Duchenne Muscular Dystrophy (DMD) Industry Impact
Chapter 2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Competition by Types, Applications, and Top Regions and Countries
2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) (Volume and Value) by Type
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Market Share by Type (2017-2022)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Type (2017-2022)
2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) (Volume and Value) by Application
2.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Market Share by Application (2017-2022)
2.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Application (2017-2022)
2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) (Volume and Value) by Regions
2.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Regions (2017-2022)
4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
4.10 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
5.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
5.1.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
5.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
5.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
5.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
5.4.1 United States Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
5.4.2 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
5.4.3 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 6 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
6.1 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
6.1.1 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
6.2 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
6.3 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
6.4 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
6.4.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
6.4.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
6.4.3 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 7 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
7.1.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
7.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
7.4.1 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.2 UK Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.3 France Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.4 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.5 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.6 Spain Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.7 Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.8 Switzerland Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
7.4.9 Poland Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 8 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
8.1 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
8.1.1 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
8.2 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
8.3 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
8.4 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
8.4.1 India Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
8.4.2 Pakistan Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
9.1 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
9.1.1 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
9.2 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
9.3 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
9.4 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
9.4.1 Indonesia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.2 Thailand Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.3 Singapore Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.4 Malaysia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.5 Philippines Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.6 Vietnam Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
9.4.7 Myanmar Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 10 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
10.1 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
10.1.1 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
10.2 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
10.3 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
10.4 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
10.4.1 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.3 Iran Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.5 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.6 Iraq Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.7 Qatar Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.8 Kuwait Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
10.4.9 Oman Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 11 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
11.1 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
11.1.1 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
11.2 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
11.3 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
11.4 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
11.4.1 Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
11.4.2 South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
11.4.3 Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
11.4.4 Algeria Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
11.4.5 Morocco Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 12 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
12.1 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
12.2 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
12.3 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
12.4 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Consumption by Top Countries
12.4.1 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
12.4.2 New Zealand Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 13 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis
13.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption and Value Analysis
13.1.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Under COVID-19
13.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Types
13.3 South America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Structure by Application
13.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume by Major Countries
13.4.1 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.2 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.3 Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.4 Chile Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.5 Venezuela Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.6 Peru Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
13.4.8 Ecuador Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Drugs for Duchenne Muscular Dystrophy (DMD) Business
14.1 Sarepta Therapeutics
14.1.1 Sarepta Therapeutics Company Profile
14.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Bristol-Myers Squibb
14.2.1 Bristol-Myers Squibb Company Profile
14.2.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.2.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 PTC Therapeutics
14.3.1 PTC Therapeutics Company Profile
14.3.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.3.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 WaVe life Science
14.4.1 WaVe life Science Company Profile
14.4.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.4.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Pfizer
14.5.1 Pfizer Company Profile
14.5.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.5.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Santhera Pharmaceuticals
14.6.1 Santhera Pharmaceuticals Company Profile
14.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Italfarmaco
14.7.1 Italfarmaco Company Profile
14.7.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Specification
14.7.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast (2023-2028)
15.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Value and Growth Rate Forecast (2023-2028)
15.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Forecast by Type (2023-2028)
15.3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Forecast by Type (2023-2028)
15.3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price Forecast by Type (2023-2028)
15.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Volume Forecast by Application (2023-2028)
15.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology

ページTOPに戻る

Table of Contents

Summary

The global Drugs for Duchenne Muscular Dystrophy (DMD) market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).

By Market Verdors:
Sarepta Therapeutics
Bristol-Myers Squibb
PTC Therapeutics
WaVe life Science
Pfizer
Santhera Pharmaceuticals
Italfarmaco

By Types:
Eteplirsen
Deflazacort
Ataluren

By Applications:
Hospitals
Clinics
Home Care

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2017-2028 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2017-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

HNY Research社のPharma & Healthcare分野での最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート

よくあるご質問

HNY Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

2023-2028年世界および地域のデュシェンヌ型筋ジストロフィー（DMD）治療薬産業の現状と展望専門市場調査報告書標準版

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

HNY Research社のPharma & Healthcare分野での最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート

よくあるご質問

HNY Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?